Abstracts Archive - Page 176 of 2425 - ACR Meeting Abstracts

Abstract Number: 1211 • ACR Convergence 2024
An Evaluation of the Efficacy, Pharmacokinetics and Safety, of the Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist RTX-GRT7039 – a Placebo-controlled Study in Patients with Osteoarthritis Knee Pain
Thor Ostenfeld¹, Stefan Ivanicius¹, Roman Stancik² and Philip G Conaghan³, ¹Grunenthal GmbH, Aachen, Germany, ²National Institute of Rheumatic Diseases, Piestany, Slovenia, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: The transient receptor potential vanilloid 1 (TRPV1) is a critical driver of osteoarthritis (OA) pain. RTX-GRT7039 is an investigational medicinal product containing the active…
Abstract Number: 1241 • ACR Convergence 2024
Optimizing Communication of Methotrexate (MTX) Side Effects: A Patient-Centered Approach Focused on Learning Styles and Preferred Language
Veena Patel¹, Sophia Dove² and Veronica Chavez³, ¹Dell Medical School - UT Health Austin, Austin, TX, ²Moody College of Communication, The University of Texas at Austin, Austin, TX, ³University of Texas - Dell Medical School, Austin, TX
Background/Purpose: Methotrexate (MTX) remains the first-line treatment for RA due to its effectiveness and affordability, but communicating its complex regimen and instructions can be challenging,…
Abstract Number: 1027 • ACR Convergence 2024
Evaluation of Health Disparities in Outcomes of Patients with Juvenile Idiopathic Arthritis
Julia Harris¹, Jade Singleton² and Sheetal Vora³, ¹Children's Mercy Kansas City, Overland Park, KS, ²Seattle Children's Hospital, Seattle, ³Atrium Health Levine Children's Hospital, Charlotte, NC
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease complicated by significant morbidity and disability with suboptimal rates of prolonged remission, decreased health-related quality…
Abstract Number: 1228 • ACR Convergence 2024
Central Pain Mechanisms and Physical Function in Early Rheumatoid Arthritis
Burcu Aydemir¹, Lutfiyya Muhammad², Jing Song³, Dorothy Dunlop⁴, Kathleen Aren⁵, Mary Carns⁵, Wendy Marder⁶, Vivian Bykerk⁷, Kevin Deane⁸, Clifton Bingham⁹ and Yvonne Lee¹, ¹Northwestern University, Chicago, IL, ²Northwestern Feinberg School of Medicine, Chicago, IL, ³Northwestern University, Worthington, MN, ⁴Northwestern University, New Haven, CT, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶University of Michigan, Ann Arbor, MI, ⁷Hospital For Special Surgery, New York, NY, ⁸University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁹Johns Hopkins University, Baltimore, MD
Background/Purpose: Despite effective control of inflammation, patients with rheumatoid arthritis (RA) may experience lingering pain and losses in physical function. Pain can occur because central…
Abstract Number: 1163 • ACR Convergence 2024
Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population
Aurélie Mourot¹, Beatrice Panuta¹, Juliette Charbonneau¹, Ange Mounkam Ngeuleu¹, Caroline Vo², Eric Rich³, Josiane Bourré-Tessier³, Edith Villeneuve³, Hélène Manganas³, Andréanne Gauthier³, Julie Morisset³, Sabrina Anh-Tu Hoa³ and Océane Landon-Cardinal³, ¹University of Montreal, Montreal, QC, Canada, ²Hôpital Charles Lemoyne, Montreal, QC, Canada, ³Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada
Background/Purpose: Antisynthetase syndrome (ASSD) is characterized by interstitial lung disease (ILD), myositis, polyarthritis, Raynaud’s phenomenon, dermatomyositis-like rash and mechanic’s hands. ILD may present with isolated…
Abstract Number: 1267 • ACR Convergence 2024
Antiphospholipid Antibody-related Clinical Manifestations Presenting During Childhood versus Adulthood: Descriptive Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Jheel Pandya¹, Danieli Andrade², Ann E. Clarke³, Maria Tektonidou⁴, Vittorio Pengo⁵, Massimo Radin⁶, Jose Pardos-Gea⁷, Nina Kello⁸, Diana Paredes-Ruiz⁹, Mª Angeles Aguirre-Zamorano¹⁰, H Michael Belmont¹¹, Paul Fortin¹², Flavio Victor Signorelli¹³, TATSUYA ATSUMI¹⁴, Zhuoli Zhang¹⁵, Maria Efthymiou¹⁶, David Branch¹⁷, Giulia Pazzola¹⁸, Angela Tincani¹⁹, Ali Duarte-Garcia²⁰, Esther Rodriguez-Almaraz²¹, Michelle Petri²², Ricard Cervera²³, Bahar Artim Esen²⁴, Guillermo Pons-Estel²⁵, Hui Shi²⁶, Yu Zuo²⁷, Rohan Willis²⁸, Pierluigi Meroni²⁹, Robert Roubey³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³² and Doruk Erkan¹, and on behalf of APS ACTION, ¹Hospital for Special Surgery, New York, NY, ²University of São Paulo, São Paulo, SP, Brazil, ³Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ⁶University of Turin, Turin, Italy, ⁷Vall d'Hebron University Hospital, Barcelona, Spain, ⁸Northwell Health, Brooklyn, NY, ⁹Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, ¹⁰IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ¹¹NYU School of Medicine, New York, NY, ¹²Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶University College London, London, United Kingdom, ¹⁷University of Utah and Intermountain Healthcare, Salt Lake City, UT, ¹⁸Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ¹⁹ASST Spedali Civili-University of Brescia, Brescia, Italy, ²⁰Mayo Clinic, Rochester, MN, ²¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²²Johns Hopkins University School of Medicine, Timonium, MD, ²³Hospital Clinic de Barcelona, Barcelona, Spain, ²⁴Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁵CREAR, Rosario, Argentina, ²⁶Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic), ²⁷University of Michigan, Ann Arbor, MI, ²⁸University of Texas Medical Branch, Galveston, TX, ²⁹IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ³⁰Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: APS ACTION Registry studies long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic autoimmune rheumatic diseases. Given autoimmune diseases present differently in…
Abstract Number: 1248 • ACR Convergence 2024
Most Prevalent Self-Reported Comorbidities Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis
Shilpa Venkatachalam¹, Jeffrey Curtis², Anne Sydor³, Erik Stone⁴, Angela Degrassi³, Esteban Rivera⁵, Laura Stradford⁶ and Kelly Gavigan³, ¹Global Healthy Living Foundation, New York, NY, ²University of Alabama at Birmingham, Hoover, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Upper Nyack, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: Many people with inflammatory arthritis live with other serious chronic conditions that may affect their quality of life and ability to effectively manage their…
Abstract Number: 1266 • ACR Convergence 2024
Anti-Mitochondrial Antibodies Associate with Disease Activity and IFNα Expression in Childhood-onset Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Javad Wahadat², Albin Bjoerk³, Sylvia Kamphuis², Marjan Versnel² and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Erasmus University Medical Center, Rotterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Extracellular mitochondria may represent a source of antigenic burden in autoimmune disorders, such as in systemic lupus erythematosus (SLE), in which those organelles, released…
Abstract Number: 1036 • ACR Convergence 2024
A Pilot Trial of Integrating Patient-Reported Outcome Measurement Information System (PROMIS®) into Rheumatology Care
Rosemary Gedert¹, Danielle Ochocki¹, Neda Kortam¹, Suiyuan Huang¹, Vivek Nagaraja², Katherine Chakrabarti¹, Julia Ford¹, Martin Garber¹, Jiha Lee¹, Vladimir Ognenovski¹, David Roofeh³, David Cella⁴ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²Mayo Clinic Arizona, Scottsdale, AZ, ³Rutgers-RWJ Medical School, New Brunswick, NJ, ⁴Northwestern University, Chicago, IL
Background/Purpose: Utilizing Patient-Reported Outcomes Measurement Information System (PROMIS®) questionnaires can enhance clinical care by measuring longitudinal changes in symptom severity as reported by the patient.…
Abstract Number: 1221 • ACR Convergence 2024
Efficacy of Immersive Virtual Reality-based Biofeedback on Chronic Pain and Daily Life Impact in Fibromyalgia: A Pilot Randomized Controlled Trial
Luca Chittaro¹, Simone Longhino², Marta Serafini¹, Sofia Cacioppo² and Luca Quartuccio³, ¹Human-Computer Interaction Lab, Department of Mathematics, Computer Science and Physics, University of Udine, Udine, Italy, ²Division of Rheumatology, Department of Medicine, University of Udine, UDine, Italy, ³Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy
Background/Purpose: Fibromyalgia (FM) affects 2% of the global population, causing chronic musculoskeletal pain, fatigue, sleep and mood disorders, significantly impacting quality of life. Although many…
Abstract Number: 1277 • ACR Convergence 2024
Why Did You Choose That Score? – Associations Between Patient Global Assessment Scores and Mental Health in Patients with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Inna Powers¹, Sonja Ziniel², Jeanelle Sheeder³, Jessica Bloom⁴ and Brian Pitts¹, ¹University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado School of Medicine, Department of Obstetrics and Gynecology, Aurora, CO, ⁴University of Colorado, Denver, CO
Background/Purpose: Rheumatic disease in childhood significantly alters a child’s quality of life. The patient global assessment (PGA) score is a clinical and research tool that…
Abstract Number: 1060 • ACR Convergence 2024
Therapeutic Hydroxychloroquine Blood Levels Predict Lower Mean Frequency of Recurrent Acute Care Utilization in Lupus
Shivani Garg¹, Giancarlo Valiente², Callie Saric¹, Betty Chewning³ and Christie Bartels⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, ³University of Wisconsin, School of Pharmacy, Madison, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Nonadherence to hydroxychloroquine (HCQ) is highly prevalent in lupus (or SLE) and two-fold higher in patients of Black race or Hispanic ethnicity. While HCQ…
Abstract Number: 1159 • ACR Convergence 2024
Anti-synthetase Syndrome (ASSD) Related Interstitial Lung Disease (ILD) in Comparison to Non-ASSD Related ILDs: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Sangmee Bae¹, Francisca Bozan², Daphne Rivero Gallegos³, Giovanni Zanframundo⁴, Sara Faghihi-Kashani⁵, iazsmin Ventura⁶, Eduardo Dourado⁷, Aravinthan Loganathan⁸, Gianluca sambataro⁹, Akira Yoshida¹⁰, Francesco Bonella¹¹, Tamera J Corte¹², Tracy J Doyle¹³, david fiorentino¹⁴, Miguel Angel Gonzalez-Gay¹⁵, marie Hudson¹⁶, Masataka Kuwana¹⁷, Antonella Notarnicola¹⁸, Andrew Mammen¹⁹, Neil McHugh²⁰, Frederick Miller²¹, Carlomaurizio Montecucco²², Chester Oddis²³, Jorge Rojas-Serrano²⁴, Jens Schmidt²⁵, Carlo Scire²⁶, Albert Selva-O’Callaghan²⁷, Victoria Werth²⁸, Lorenzo Cavagna²⁹ and Rohit Aggarwal³⁰, ¹UCLA, Los Angeles, CA, ²Hospital Clinico Universidad de Chile, Santiago, Chile, ³INER, Ciudad de México, Mexico State, Mexico, ⁴Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ⁶Section of Rheumatology, University of Chicago, Chicago, IL, ⁷Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, ⁸RUH, Middle Park, Queensland, Australia, ⁹University of Catania, Catania, Italy, ¹⁰Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ¹¹Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ¹²Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, ¹³Brigham and Women's Hospital, West Roxbury, MA, ¹⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ¹⁵University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁶McGill University, Montreal, QC, Canada, ¹⁷Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ¹⁹NIH, Bethesda, MD, ²⁰University of Bath, Bath, United Kingdom, ²¹NIH, NIEHS, Chapel Hill, NC, ²²IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²⁴National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, ²⁵University Medical Center Goettingen, Göttingen, Germany, ²⁶University of Milano Bicocca, Milan, Italy, ²⁷Internal Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain, ²⁸University of Pennsylvania, Wynnewood, PA, ²⁹University of Pavia, Pavia, Italy, ³⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Anti-synthetase syndrome (ASSD) is a subset of idiopathic inflammatory myopathy characterized by autoantibodies directed against aminoacyl tRNA synthetases. Interstitial lung disease (ILD) can be…
Abstract Number: 1258 • ACR Convergence 2024
Investigating Factors Associated with Gaps in Care in Adolescents and Young Adults with Systemic Lupus
Tamar Rubinstein¹, Avni Dave², Terrence Calistro³, Kimberly Rapoza³, Joyce Hui-Yuen⁴, Emily Masi⁵, Shari Salzhauer Berkowitz³, Zanab Mian⁶ and Kathleen Kenney-Riley⁷, ¹Albert Einstein College of Medicine, White Plains, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Mercy University, Dobbs Ferry, NY, ⁴North Shore LIJ Health System, Great Neck, NY, ⁵Cohen Children's Medical Center, Floral Park, NY, ⁶Cohen Children's Medical Center, Lake Success, NY, ⁷Albert Einstein College of Medicine, Port Chester, NY
Background/Purpose: Adolescents and young adults (AYA) with systemic lupus (SLE) are at an especially high risk for disengagement in care, a possible cause of the…
Abstract Number: 1279 • ACR Convergence 2024
Cerebrovascular Accidents in Pediatric and Adult Systemic Lupus Erythematosus: A Comparison of Epidemiology and Outcomes
Ekemini Ogbu¹, Jareen Meinzen-Derr², Michael Wagner², Rashmi Sahay², Dhriti Sharma², J Michael Taylor², Sudhakar Vadivelu³, Mekibib Altaye² and hermine brunner¹, ¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Cerebrovascular accidents (CVA) are one of the most devastating neurologic manifestations of childhood-onset systemic lupus erythematosus (cSLE). The spectrum of CVA in cSLE (CVAcSLE)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].